Canagliflozin-current status in the treatment of type 2 diabetes mellitus with focus on clinical trial data.
about
A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus.Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit?Alpha1A-adrenoceptor antagonist improves underactive bladder associated with diabetic cystopathy via bladder blood flow in rats.
P2860
Canagliflozin-current status in the treatment of type 2 diabetes mellitus with focus on clinical trial data.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Canagliflozin-current status i ...... focus on clinical trial data.
@ast
Canagliflozin-current status i ...... focus on clinical trial data.
@en
type
label
Canagliflozin-current status i ...... focus on clinical trial data.
@ast
Canagliflozin-current status i ...... focus on clinical trial data.
@en
prefLabel
Canagliflozin-current status i ...... focus on clinical trial data.
@ast
Canagliflozin-current status i ...... focus on clinical trial data.
@en
P2093
P2860
P356
P1476
Canagliflozin-current status i ...... focus on clinical trial data.
@en
P2093
Dharamvir Singh Arya
Jagriti Bhatia
Nanda Gamad
Saurabh Bharti
P2860
P304
P356
10.4239/WJD.V5.I3.399
P577
2014-06-01T00:00:00Z